REGENXBIO Q2 2026 Earnings: $100 Million Milestone Drives a Quarterly Profit

REGENXBIO (Nasdaq: RGNX) reported Q2 2026 revenue of $108.0 million, up approximately 406% from $21.4 million a year earlier, while diluted EPS improved to $0.43 from a loss of $1.38. A $100.0 million AbbVie development milestone drove the revenue increase and helped the company swing to net income, while July funding lifted pro forma liquidity to approximately $313 million.

Core Financial Results

The milestone associated with dosing the first participant in the NAAVIGATE study accounted for most of the quarter’s revenue. This benefit was partially offset by a $16.7 million decline in ZOLGENSMA royalty revenue following the January 2026 expiration of licensed U.S. patents.

Operating expenses decreased approximately 7% as lower research and development spending more than offset higher general and administrative costs. R&D expense declined to $56.1 million from $59.5 million, mainly due to lower manufacturing and clinical trial expenses for sura-vec and NAVSUNLI, while G&A expense rose to $21.6 million from $19.9 million because of personnel, commercialization and advisory costs.

Pipeline and Program Progress

RGX-202 for Duchenne muscular dystrophy

The Phase III AFFINITY DUCHENNE trial met its primary endpoint with high statistical significance of p<0.0001. REGENXBIO also reported a favorable interim safety profile and a statistically significant correlation between microdystrophin expression and one-year functional improvement, although the cited functional analysis included nine participants.

Enrollment in the confirmatory study was completed ahead of schedule in June. The company plans to initiate a biologics license application under the accelerated approval pathway in Q3 2026, with potential approval in the second half of 2027. It also expects to begin the ex-U.S. AFFINITY RISE study in the first half of 2027 to support global regulatory submissions.

Sura-vec for retinal diseases

For wet age-related macular degeneration, REGENXBIO and AbbVie expect Q4 2026 topline data from the pivotal ATMOSPHERE and ASCENT trials. Global regulatory submissions are planned for 2027. Earlier-stage follow-up showed stable to improved visual acuity and reduced anti-VEGF treatment burden through five years at doses similar to those used in the pivotal trials, apart from one reported participant exception.

For diabetic retinopathy, the first patient was dosed in the Phase IIb/III NAAVIGATE study in June, triggering the $100.0 million AbbVie milestone. Long-term ALTITUDE data showed a durable safety and efficacy profile through 2.5 years at the dose being evaluated in NAAVIGATE.

NAVSUNLI for Hunter syndrome

Following a July Type A meeting, the FDA reaffirmed that no additional studies are required for the NAVSUNLI, or RGX-121, BLA resubmission. REGENXBIO plans to resubmit the application in Q3 2026 with longer-term efficacy, safety and participant imaging data. A post-approval confirmatory study will be discussed during the BLA review.

Milestone Recognition Created Profit Before the Cash Arrived

REGENXBIO recognized the $100.0 million AbbVie milestone as Q2 revenue, but the cash was not received until July. This timing contributed to accounts receivable rising to $106.8 million at June 30 from $26.4 million at the end of 2025, while cash, cash equivalents and marketable securities declined to $105.5 million from $240.9 million as operating activities consumed cash during the first half.

The milestone was therefore central to Q2 profitability but did not immediately strengthen the June 30 cash balance. The company also remained unprofitable on a year-to-date basis: first-half revenue was $114.4 million, up approximately 4%, while the first-half net loss was $67.3 million compared with $64.8 million a year earlier.

In July, REGENXBIO received the milestone payment and approximately $107.8 million in estimated net proceeds from an offering of common stock and pre-funded warrants. Including those amounts, pro forma June 30 liquidity was approximately $313 million.

Cash Runway Guidance

REGENXBIO expects its available resources to fund current operating plans into Q4 2027. The additional funding will also support the planned initiation of the AFFINITY RISE study in the first half of 2027.

Recent Insider Transactions

The supplied insider data reports 129,553 shares purchased across 12 transactions and 78,927 shares sold across four transactions during the past six months, resulting in 50,626 net shares purchased. Total insider holdings were reported at approximately 3.38 million shares, but the aggregate includes different transaction types such as awards, derivative exercises and sales.

The grants and derivative exercises are not directly comparable with sales and should not be interpreted on their own as indicating management’s outlook.

Risks Investors Need to Watch

• Milestone-dependent revenue: The $100.0 million AbbVie milestone represented most of Q2 revenue and was the primary reason for the quarterly profit. First-half results remained loss-making, making the timing and size of future collaboration payments important.
• Royalty pressure: ZOLGENSMA royalty revenue declined by $16.7 million after licensed U.S. patents expired. REGENXBIO is entitled to royalties on certain ITVISMA sales, but the quarter’s disclosed results do not show those royalties fully offsetting the decline.
• Regulatory and clinical execution: The RGX-202 and NAVSUNLI BLA processes remain subject to regulatory review, while pivotal wet AMD results are not expected until Q4 2026. Delays or unfavorable data could alter development timelines.
• Cash use and dilution: Liquidity fell substantially during the first half as the company funded operations. The July offering extended the runway but involved issuing common stock and pre-funded warrants.

Summary

REGENXBIO’s Q2 2026 profit was driven primarily by the $100.0 million NAAVIGATE milestone rather than broad recurring revenue growth. July’s milestone receipt and equity offering materially improved liquidity and extended the expected runway into Q4 2027. The next major operating checkpoints are the Q3 2026 regulatory submissions for RGX-202 and NAVSUNLI, followed by pivotal wet AMD data expected in Q4 2026.